DAWN icon

DAWN

Lightning icon

21.49 USD

-0.05%

Today

+0.00%

1D

Market is closed

Sun

Closed

Mon

4:30 PM ~ 11:00 PM

Tue

4:30 PM ~ 11:00 PM

Wed

4:30 PM ~ 11:00 PM

Thu

4:30 PM ~ 11:00 PM

Fri

4:30 PM ~ 11:00 PM

Sat

Closed

Loading chart...
1D
5D
1M
3M
1Y
MAX

Information

Name

Day One Biopharmaceuticals Leveraged

Currency

USD

Standard Leverage

1X

Lightning Icon

Enhanced Leverage

3X

Lightning Icon

Overnight Fees Buy

-0.0191%

Overnight Fees Sell

0.0024%

Market Cap

2.22B

Avg Daily Volume

1.76M

52 Week High

21.47 USD

52 Week Low

5.635 USD

Trading Hours

See hours

Overnight Fees Calculator

ExposureUnits
USD
Daily Overnight Fee %Daily Overnight Fee $
BUYS-0.01910%$(0.191)
SELLS0.00240%$0.024

*Results displayed are estimates. Actual fees may differ from those shown as market conditions change.

Business Summary

Day One Biopharmaceuticals, Inc., a commercial-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for childhood and adult diseases with equal intensity in the United States. The company's lead product candidate is tovorafenib, an oral and brain-penetrant type II rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed or refractory low-grade glioma; and Ipsen, a frontline raf-altered pLGG which is in Phase III clinical trial stage. It is also developing DAY301, a PTK7 targeted ADC composed of a novel humanized anti-PTK7 immunoglobulin G1 monoclonal antibody conjugated with a topoisomerase I inhibitor via a highly stable and hydrophilic modified valine-alanine (VA) cleavable linker for the treatment of patients with advanced solid tumors; and Emi-Le, an antibody-drug conjugate that targets B7- H4 conjugated to an auristatin anti-tubulin payload as a component of a proprietary linker-payload platform developed by Mersana Therapeutics that is in Phase 1 clinicla trial for the treatment of breast cancer, ovarian cancer, endometrial cancer, and adenoid cystic carcinoma (ACC). Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.

Top News

Servier and Day One Biopharmaceuticals announce acquisition to expand Servier’s rare oncology portfolio

tradingview.com

1mo ago

No Image

Day One Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Outlook and Revenue Guidance

tradingview.com

1mo ago

No Image

Day One To Report Fourth Quarter and Full-Year 2025 Financial Results Tuesday, February 24, 2026

tradingview.com

1mo ago

No Image

Show more

Frequently Asked Questions

What are healthcare stocks and why are they important to investors?

Healthcare stocks include pharmaceutical companies, biotech firms, hospitals, and medical device manufacturers.


Are healthcare stocks less volatile?

Generally yes. Because healthcare is a necessity, demand remains relatively steady, making the sector less sensitive to economic cycles.


What drives growth in healthcare investments?

Aging populations, technological advancements, and increased healthcare spending contribute to long-term growth in the sector.


What are the risks of investing in healthcare?

Regulatory changes, drug approval delays, and legal challenges can affect the profitability and stock prices of healthcare companies.